Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial
John R. Mackey, Miguel Martín(Hospital General Universitario Gregorio Marañón), Tadeusz Pieńkowski, Janusz Rolski(Lublin Oncology Center), Jean-Paul Guastalla(Centre Léon Bérard), Amer Sami, John A. Glaspy(Research International (United States)), É Juhos(National Institute of Oncology), Andrew Wardley(The Christie Hospital), Tommy� Fornander(Stockholm South General Hospital), John D. Hainsworth(Sarah Cannon), Robert E. Coleman(Weston Park Cancer Centre), Manuel Modiano(Arizona Research Center), J. Vinholes(Hospital de Clínicas de Porto Alegre), Tamás Pintér(Petz Aladár Megyei Oktató Kórház), Álvaro Rodríguez-Lescure(Hospital General Universitario de Elche), Bruce Colwell(Queen Elizabeth II Health Sciences Centre), Whitlock Pierre, Louise Provencher(Hôpital du Saint-Sacrement), Kara Laing(Dr. H. Bliss Murphy Cancer Centre), David Walde(Essar Steel Algoma (Canada)), C. H. G. Price(At Bristol), Judith Hugh, Barrett H. Childs(Sanofi (United States)), Kimberly Bassi(Sanofi (United States)), Mary-Ann Lindsay(Translational Research in Oncology), Véronique Wilson(Translational Research in Oncology), Matthieu Rupin(Translational Research in Oncology), Vincent Houé(Translational Research in Oncology), Charles L. Vogel(Lynn University)
Cited by 221
Abstract
Related Papers
No related papers found
Powered by citation graph analysis